Please assess the completion status of the following clinical trial:

Trial Title: Luteal Phase-start Ovarian Stimulation With Corifollitropin Alfa

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy eligible oocyte donors~2. Age 18-34 years~3. AFC \>12 and AMH\>1.5 ng/ml~4. BMI 19-28kg/m2~5. Body weight \>60kg~6. Both ovaries present~7. Willing to participate in the study~8. Willing to use non-hormonal contraception or not needing contraception Recipients will be eligible only if their partners' sperm which will be used for ICSI will be normal. Couples will be excluded in case of moderate to severe oligoasthenospermia.~Exclusion Criteria:~1. Endometriosis~2. AFC\>20~3. PCOS~4. Low ovarian reserve~5. Endocrine abnormalities~6. Hormonal contraception~7. Contraindication of hormonal treatment~8. History of Ovarian Hyperstimulation Syndrome or hyper-response (\> 30 follicles .~11mm)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Early follicular phase protocol (Type: ACTIVE_COMPARATOR): On day 2 or 3 of the menstrual cycle, following baseline blood sampling, a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
- Luteal phase protocol (Type: EXPERIMENTAL): Following baseline blood sampling on cycle day 2 of 3 of the menstrual cycle, patients will be followed up with blood and ultrasound from cycle day 10 onwards till the detection of serum LH peak. LH peak will be defined as an increase in serum LH above 20IU/LH. Five (5) days after the LH peak a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).